- About us
- Clinical trials
- News & Publications
The immune cytokine Interleukin-15 (IL-15) has a strong, clinically validated rationale in immuno-oncology. Along with Interleukin-2 (IL-2), IL-15 activity increases the number of cytotoxic T cells and NK cells, the two most important cells for driving an anti-cancer immune response. This T and NK cell expansion is the result of IL-15 binding to its IL-15 alpha chain receptor in conjunction with binding to its shared IL-2/IL-15 beta gamma receptor on the surface of T and NK cells.
Mobilizing the T and NK cell populations has the potential to complement and enhance current immuno-oncology treatment approaches, such as immune checkpoint inhibitors, where treatment is currently only successful in 15-30% of patients.